Jame Abraham/my.clevelandclinic.org
Jul 14, 2025, 08:10
Jame Abraham: A Moving Target in the Era of Antibody-Drug Conjugates
Jame Abraham, Chairman and Professor of Department of Hematology and Medical Oncology at Cleveland Clinic, shared on LinkedIn about a recent paper by Marko Velimirovic published in JCO:
“Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates.”
Authors: Marko Velimirovic and Jame Abraham
More posts featuring Jame Abraham.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 14, 2025, 08:10
Jul 14, 2025, 07:53
Jul 14, 2025, 03:39
Jul 13, 2025, 18:34
Jul 13, 2025, 17:58